We analyzed two HNSCC neoadjuvant immunotherapy datasets: GSE281729 (anti-PD-1 monotherapy vs. anti-PD-1 + IDO inhibitor) and GSE195832 (anti-PD-1 monotherapy vs. anti-PD-1 + Tadalafil). This evidence concerns the gene IDO1 and head and neck squamous cell carcinoma.